Volume 26, Number 3—March 2020
Research
Genomic and Phenotypic Variability in Neisseria gonorrhoeae Antimicrobial Susceptibility, England
Table 3
Characteristics |
Total |
Cluster 1, n = 57, no. (%) |
Cluster 2, n = 26, no. (%) |
p value† |
Year | ||||
2013 | 26 | 26 (45.6) | 0 | <0.001‡ |
2014 | 29 | 14 (24.6) | 15 (57.7) | |
2015 | 20 | 10 (17.5) | 10 (38.5) | |
2016 |
8 |
7 (12.3) |
1 (3.8) |
|
Sex and sexual orientation | ||||
MSM | 49 | 24 (42.1) | 25 (96.2) | <0.001‡ |
MSW | 21 | 21 (36.8) | 0 | |
F |
13 |
12 (21.1) |
1 (3.8) |
|
Clinic location | ||||
Outside London | 43 | 38 (66.7) | 5 (19.2) | <0.001‡ |
London |
40 |
19 (33.3) |
21 (80.8) |
|
Age, y | ||||
≤24 | 28 | 23 (40.4) | 5 (19.2) | 0.081 |
25–34 | 29 | 20 (35.1) | 9 (34.6) | |
≥35 |
26 |
14 (24.6) |
12 (46.2) |
|
Ethnicity | ||||
White | 59 | 37 (68.5) | 22 (84.6) | 0.408‡ |
Black Caribbean | 6 | 6 (11.1) | 0 | |
Black Other | 2 | 2 (3.7) | 0 | |
Asian | 5 | 4 (7.4) | 1 (3.8) | |
Other | 4 | 2 (3.7) | 2 (7.7) | |
Mixed |
4 |
3 (5.6) |
1 (3.8) |
|
Place of birth | ||||
United Kingdom | 40 | 30 (52.6) | 10 (38.5) | 0.262‡ |
Not United Kingdom | 40 | 26 (45.6) | 14 (53.9) | |
Unknown |
3 |
1 (1.7) |
2 (7.7) |
|
Symptomatic infection | ||||
No | 28 | 13 (24.5) | 15 (57.7) | 0.004 |
Yes |
51 |
40 (75.5) |
11 (42.3) |
|
New STI diagnosed <1 year, excluding HIV | ||||
No | 68 | 51 (89.5) | 17 (65.4) | 0.013‡ |
Yes |
15 |
6 (10.5) |
9 (34.6) |
|
HIV status | ||||
Negative or unknown | 70 | 53 (93.0) | 17 (65.4) | 0.003‡ |
Positive |
13 |
4 (7.0) |
9 (34.6) |
|
Number of sexual partners in the United Kingdom <3 mo of N. gonorrhea diagnosis | ||||
0 | 6 | 6 (13.3) | 0 | 0.675‡ |
1 | 19 | 16 (35.6) | 3 (33.3) | |
≥2 |
29 |
23 (51.1) |
6 (66.7) |
|
Travel-associated sexual partnership | ||||
No | 43 | 34 (75.6) | 9 (100) | 0.178‡ |
Yes | 11 | 11 (24.4) | 0 |
*Bold text indicates statistical significance (i.e., p<0.05 and 95% CI does not cross 1). MSM, men who have sex with men; MSW, men who reported sexual activity exclusively with women.
†Calculated using χ2 test, except where noted.
‡Calculated using Fisher exact test.
Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.